Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study
Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally. For the treatment of SARS-CoV-2 pneumonia, two commonly used antiviral...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Infection and Public Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034124003174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850066704525164544 |
|---|---|
| author | Wei Yang Weiting Zhang Jing Zhou Xinyue Ma Changsong Wang Mingyan Zhao Kaijiang Yu |
| author_facet | Wei Yang Weiting Zhang Jing Zhou Xinyue Ma Changsong Wang Mingyan Zhao Kaijiang Yu |
| author_sort | Wei Yang |
| collection | DOAJ |
| description | Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally. For the treatment of SARS-CoV-2 pneumonia, two commonly used antiviral drugs in the clinic are nirmatrelvir/ritonavir(Paxlovid) and Azvudine, while the therapeutic efficacy of the two drugs and their impact on patient prognosis remain inconclusive. Therefore, the aim of this study is to investigate the effects of two antiviral drugs, Azvudine and Paxlovid, on the disease development and prognosis of patients with COVID-19. Methods: This study collected and analyzed in Inner Mongolia hospital treated 267 cases of COVID - 19 patients. According to the use of antiviral medications, the participants in this experiment were split into the Azvudine and Paxlovid groups. The effectiveness of the medications was evaluated using the length of hospitalization, Nucleic acid into negative time for the first time, and laboratory indices such as total protein, lymphocytes, leukocytes, albumin, creatinine, and platelets. Results: Compared with the Azvudine group, patients in the Paxlovid group had a shorter recovery time, a higher degree of rise in lymphocytes, a faster recovery of the immune system, a lower rise in creatinine, and a lesser renal burden, but patients in the Paxlovid group had a greater decrease in total protein. Conclusion: In assessing patient conditions for treatment selection, Paxlovid may be preferable for individuals with renal insufficiency or those exhibiting compromised immune responses. Conversely, for patients experiencing malnutrition or cirrhotic hypoproteinemia, Azvudine could be considered to mitigate the reduction in protein levels. |
| format | Article |
| id | doaj-art-82a6fa43e98948c89581950ca286dbcd |
| institution | DOAJ |
| issn | 1876-0341 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Infection and Public Health |
| spelling | doaj-art-82a6fa43e98948c89581950ca286dbcd2025-08-20T02:48:39ZengElsevierJournal of Infection and Public Health1876-03412024-12-01171210258310.1016/j.jiph.2024.102583Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective studyWei Yang0Weiting Zhang1Jing Zhou2Xinyue Ma3Changsong Wang4Mingyan Zhao5Kaijiang Yu6Department of Critical Care Medicine of the First Affiliated Hospital of Harbin Medical University, Hei Longjiang, ChinaFirst Affiliated Hospital of Harbin Medical University, Hei Longjiang, ChinaFirst Affiliated Hospital of Harbin Medical University, Hei Longjiang, ChinaFirst Affiliated Hospital of Harbin Medical University, Hei Longjiang, ChinaDepartment of Critical Care Medicine of the First Affiliated Hospital of Harbin Medical University, Hei Longjiang, ChinaDepartment of Critical Care Medicine of the First Affiliated Hospital of Harbin Medical University, Hei Longjiang, China; Corresponding authors.First Affiliated Hospital of Harbin Medical University, the chairman of Critical Care Medicine at Harbin Medical University. The president of Critical Care Medicine Professional Committee of China Anti-cancer Association, Hei Longjiang, China; Corresponding authors.Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally. For the treatment of SARS-CoV-2 pneumonia, two commonly used antiviral drugs in the clinic are nirmatrelvir/ritonavir(Paxlovid) and Azvudine, while the therapeutic efficacy of the two drugs and their impact on patient prognosis remain inconclusive. Therefore, the aim of this study is to investigate the effects of two antiviral drugs, Azvudine and Paxlovid, on the disease development and prognosis of patients with COVID-19. Methods: This study collected and analyzed in Inner Mongolia hospital treated 267 cases of COVID - 19 patients. According to the use of antiviral medications, the participants in this experiment were split into the Azvudine and Paxlovid groups. The effectiveness of the medications was evaluated using the length of hospitalization, Nucleic acid into negative time for the first time, and laboratory indices such as total protein, lymphocytes, leukocytes, albumin, creatinine, and platelets. Results: Compared with the Azvudine group, patients in the Paxlovid group had a shorter recovery time, a higher degree of rise in lymphocytes, a faster recovery of the immune system, a lower rise in creatinine, and a lesser renal burden, but patients in the Paxlovid group had a greater decrease in total protein. Conclusion: In assessing patient conditions for treatment selection, Paxlovid may be preferable for individuals with renal insufficiency or those exhibiting compromised immune responses. Conversely, for patients experiencing malnutrition or cirrhotic hypoproteinemia, Azvudine could be considered to mitigate the reduction in protein levels.http://www.sciencedirect.com/science/article/pii/S1876034124003174SARS-CoV-2 pneumoniaPaxlovidAzvudine |
| spellingShingle | Wei Yang Weiting Zhang Jing Zhou Xinyue Ma Changsong Wang Mingyan Zhao Kaijiang Yu Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study Journal of Infection and Public Health SARS-CoV-2 pneumonia Paxlovid Azvudine |
| title | Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study |
| title_full | Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study |
| title_fullStr | Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study |
| title_full_unstemmed | Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study |
| title_short | Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study |
| title_sort | comparison of the therapeutic effect of paxlovid and azvudine in the treatment of covid 19 a retrospective study |
| topic | SARS-CoV-2 pneumonia Paxlovid Azvudine |
| url | http://www.sciencedirect.com/science/article/pii/S1876034124003174 |
| work_keys_str_mv | AT weiyang comparisonofthetherapeuticeffectofpaxlovidandazvudineinthetreatmentofcovid19aretrospectivestudy AT weitingzhang comparisonofthetherapeuticeffectofpaxlovidandazvudineinthetreatmentofcovid19aretrospectivestudy AT jingzhou comparisonofthetherapeuticeffectofpaxlovidandazvudineinthetreatmentofcovid19aretrospectivestudy AT xinyuema comparisonofthetherapeuticeffectofpaxlovidandazvudineinthetreatmentofcovid19aretrospectivestudy AT changsongwang comparisonofthetherapeuticeffectofpaxlovidandazvudineinthetreatmentofcovid19aretrospectivestudy AT mingyanzhao comparisonofthetherapeuticeffectofpaxlovidandazvudineinthetreatmentofcovid19aretrospectivestudy AT kaijiangyu comparisonofthetherapeuticeffectofpaxlovidandazvudineinthetreatmentofcovid19aretrospectivestudy |